financetom
Business
financetom
/
Business
/
Bionano Genomics Offers $3 Million of Shares, Warrants
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bionano Genomics Offers $3 Million of Shares, Warrants
Nov 3, 2024 3:52 PM

12:19 PM EDT, 10/31/2024 (MT Newswires) -- Bionano Genomics ( BNGO ) said Thursday it is offering 9.88 million common shares and series C and series D warrants, each to purchase additional 9.88 million shares, in a registered direct offering for $3 million.

Shares and warrants will be sold separately, with both series having an exercise price of $0.3039 per share, the company said in a regulatory filing.

The series C warrants expire five years after stockholder approval, while the series D warrants expire 18 months after approval, Bionano said.

Bionano plans to use the net proceeds, together with its existing cash and cash equivalents and available-for-sale securities, for general corporate purposes.

Bionano shares fell more than 11% in recent trading.

Price: 0.30, Change: -0.04, Percent Change: -11.30

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Highview Merger Corp. to Begin Separate Trading of Shares and Warrants from October 2
BRIEF-Highview Merger Corp. to Begin Separate Trading of Shares and Warrants from October 2
Sep 30, 2025
Sept 30 (Reuters) - Highview Merger Corp: * HIGHVIEW MERGER CORP. ANNOUNCES THE SEPARATE TRADING OF ITS CLASS A ORDINARY SHARES AND WARRANTS, COMMENCING ON OR ABOUT OCTOBER 2, 2025 Source text: Further company coverage: ...
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Sep 30, 2025
Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a Nasdaq-listed biotechnology company ZURICH, Sept. 30, 2025 /PRNewswire/ --NLS Pharmaceutics Ltd. (NLS), a Swiss clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, and Kadimastem Ltd. (TASE: KDST) (Kadimastem), an advanced clinical-stage cell therapy company developing...
Stella-Jones Expands its Utility Product Offering with an Agreement to Acquire Brooks Manufacturing Co.
Stella-Jones Expands its Utility Product Offering with an Agreement to Acquire Brooks Manufacturing Co.
Sep 30, 2025
MONTREAL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Stella-Jones Inc. ( STLJF ) (“Stella-Jones” or “the Company”) announced today that it has entered into a definitive agreement to acquire the assets of Brooks Manufacturing Co. (“Brooks”), a manufacturer of treated wood distribution crossarms and transmission framing components located in the United States. This transaction marks another significant step in the Company’s...
Form 8.3 - Dalata Hotel Group plc
Form 8.3 - Dalata Hotel Group plc
Sep 30, 2025
LONDON--(BUSINESS WIRE)--   Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved